1. A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer (AiPCa));Small;Proc Am Soc Clin Oncol,2003
2. Dendreon Corporation. Update on interim survival data from trial D9901. Provenge (APC8015) extends survival in advanced prostate cancer by over eight months in patients with Gleason Scores of seven (7) and less [press release] Seattle: Dendreon Corporation, January 12, 2004.
3. Dendreon Corporation. Final three-year survival analysis shows statistical significance in favor of provenge in overall intent-to-treat population [press release]. Seattle: Dendreon Corporation, October 28, 2004.
4. Gonadotropin-releasing hormone: physiological and endocrinological aspects;Klingmuller;Recent Results Cancer Res,1992
5. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues;Weckermann;Eur Urol,2004